We are delighted to announce that 3 abstracts using data from the International Severe Asthma Registry (ISAR) are now published in a supplement of the European Respiratory Journal!
Link to Journal: https://lnkd.in/eS_ePv5M
Link to ISAR webpage: https://lnkd.in/eVHzgC6M
ERS 2021 abstracts:
1. Baseline characteristics of severe asthma patients initiating biologic treatment worldwide (BEAM):
Link: https://lnkd.in/egB37Hsz
2. Comparative effectiveness of anti-IL5/5R versus anti-IgE in patients eligible for both (FIRE):
Link: https://lnkd.in/evj9VWkv
3. Characterisation of severe, steroid-dependent asthma patients who initiate biologics versus those who do not (GLITTER):
Link: https://lnkd.in/eWAYbdDM
Description of ISAR:
ISAR is the first global adult severe asthma registry that stores standardized severe asthma data which can be shared for clinical and research purposes. The Delphi method was used to identify a standardized set of core variables to be collected by registries contributing to ISAR. ISAR currently has 25 collaborating countries in the Americas, Asia, Australasia, Europe and the Middle East. ISAR’s research is governed by the Respiratory Effectiveness Group via the Anonymised Data Ethics and Protocol Transparency (ADEPT) committee and is overseen by the ISAR steering committee (ISC) consisting of global severe asthma experts.
Link to ISAR: www.isaregistries.org
#research #healthcare #database #asthma #biologics #ISAR